- Outer Bio retains donated human pores and skin alive exterior the physique for 4 weeks
- The Massachusetts startup has raised $23 million and screens 750 million compounds a 12 months with AI
- It joins a wave of musicians shifting from co-signs to cap tables, however this one is science-first
Stefani Germanotta has spent a decade constructing Haus Labs into one of many extra credible superstar magnificence manufacturers in the marketplace. What nearly no person knew is that she has additionally spent six years on the board of a biotech startup making an attempt to maintain human pores and skin alive exterior the physique for a month at a time.
Germanotta, higher often called Woman Gaga, launched the world to Outer Bio and its discovery platform, Yuna, in an Instagram submit on August 21.
“Meet Outer Bio and Yuna. We’re constructing the way forward for pores and skin well being,” she wrote. The corporate, legally named Outer Biosciences, was co-founded in 2020 by her fiancé, Michael Polansky, alongside chief scientist Kyung-Jin Jang, chief expertise officer Chris Hinojosa, and chief enterprise officer Stanley King.
Polansky serves as chief government; Germanotta sits on the board.
A special sort of superstar biotech
Musicians turning fandom into funding shouldn’t be new. Tech Funding Information has tracked Adele backing London royalty-tracking startup Audoo alongside Elton John and U2’s Adam Clayton, and Kesha launching her personal creator-rights platform, Smash, after years combating to reclaim possession of her personal work. Selena Gomez took an analogous founder route with the psychological well being startup Wondermind.
Elsewhere, the superstar cap desk has develop into its personal distribution technique: when AI procuring app Phia disclosed the roughly 30 cultural figures behind its $35.5 million Collection A, from Sydney Sweeney to Priyanka Chopra Jonas, the names had been the advertising.
Outer Bio doesn’t match that mould. It has no shopper product, no retail launch and, based on Polansky’s interview with TechCrunch, was intentionally stored quiet even from shut associates, for years.
Germanotta’s function has been restricted to the boardroom: she shouldn’t be among the many 4 folks TechCrunch names as 2020 co-founders, and an organization spokesperson confirmed to Billboard solely that she holds a board seat.
Protecting donated pores and skin alive for a month
The corporate’s expertise centres on Yuna, a platform that retains donated pores and skin functioning exterior the physique, or “ex vivo,” constructed from surgically discarded tissue, largely leftover materials from cosmetic surgery, sourced by biobanks working beneath institutional assessment board oversight. Pores and skin faraway from the physique sometimes dies inside a few week.
Outer Bio says its proprietary assist system, which retains vitamins shifting into the tissue and waste shifting out, extends that window to roughly 4 weeks whereas preserving the tissue’s authentic molecular construction.
Sluggish organic processes, power irritation, collagen remodelling, ageing-related tissue change and barrier restore, unfold over weeks, not days. Researchers can induce ultraviolet harm in residing tissue after which monitor the stress and restoration response because it unfolds, reasonably than counting on the short-lived assays that dominate the trade right this moment.
Layered on prime is a machine-learning system that may, Outer Bio claims, computationally pre-screen round 750 million compounds a 12 months, narrowing an unlimited chemical universe all the way down to a shortlist that then will get examined towards the residing tissue. Outcomes feed again into the mannequin proper or unsuitable, sharpening the following spherical of predictions.
Polansky says the loop now produces a brand new candidate roughly each six weeks, up from a few leads each eighteen months when the corporate relied on handbook literature mining.
Outer Bio is chasing beauty components reasonably than medication; it skips the FDA approval course of solely. What it could actually’t skip is security testing: a candidate wants a standardised trade identify and clearance beneath pointers set by the Organisation for Financial Co-operation and Growth, the Paris-based physique whose member states settle for one another’s correctly run research.
Solely after that may a associate model license or purchase the ingredient and switch it right into a serum or cream. 4 of the six present leads are already shifting by that course of. The corporate says it’s producing income right this moment by analysis collaborations, together with one with a pharmaceutical associate investigating why sure most cancers medication set off extreme pores and skin rashes, although most particular person companions haven’t been named publicly named.
What comes subsequent
Outer Bio has raised roughly $23 million to this point from early backers, together with Wing Ventures, Initialized Capital, and Polansky’s personal agency, Hawktail, amongst others. It employs 19 folks, nearly all of whom are primarily based simply exterior Cambridge, Massachusetts.
The method sits inside a wider wave of AI-driven organic discovery that TFN has tracked intently: Proxima raised $80 million to design medication round protein interactions, whereas Chai Discovery tripled its valuation to $3.8 billion in seven months, pushed by its AI molecule-design platform.
Each are pursuing therapeutics at a scale far past Outer Bio’s present ambitions; Outer Bio’s method is narrower and, for now, squarely targeted on pores and skin.
Whether or not that narrower focus helps or hurts is genuinely unclear. Philadelphia-based rival Vivodyne, which builds lab-grown organ tissue reasonably than working with donated human pores and skin, has raised near $80 million of its personal, led by Khosla Ventures.
Outer Bio’s edge, if it has one, is that its dataset doesn’t exist anyplace else: no scraped web of biology to lean on, simply years of amassed tissue-response knowledge {that a} competitor can’t merely obtain.
Germanotta’s identify is what acquired folks to look. What holds their consideration, or doesn’t, is a Yuna preprint printed earlier this 12 months that validated the tissue platform itself however stopped wanting validating the AI discovery engine on prime of it. That’s the hole between a good suggestion and a confirmed one, and proper now Outer Bio continues to be on the unsuitable facet of it.
